Arctic Bioscience AS

ABS · Oslo Børs · Healthcare

2.80NOK 0.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −18.1%

Performance

1 month

+1.8%

1 year

−18.1%

3 years, per year

−32.2%

5 years, per year

−31.5%

Largest fall, 3 years

−91.7%

Below the peak now

−90.7%

Volatility, 1 year

74.8%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.5

Dividend yield

0.0%

Return on equity

−10.9%

Net margin

−101.3%

Market value

8 m USD

Quality, value and trend

Where Arctic Bioscience stands against every Nordic stock today. 100 is best.

Quality54

Profitability and a sound balance sheet over time. Better than 54% of Nordic stocks.

Value45

The price measured against earnings, assets and cash flow. Better than 45% of Nordic stocks.

Trend18

The price development over the past year. Better than 18% of Nordic stocks.

Combined27

Quality, value and trend together. Better than 27% of Nordic stocks.

About Arctic Bioscience

Arctic Bioscience AS is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 19 employees.

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis